In Brief: House oversight hearing
This article was originally published in The Gray Sheet
Executive Summary
House oversight hearing: Rep. Joe Barton's (R-Tex.) House Commerce/Oversight Subcommittee will hold a hearing May 25 on drugs and biologics. Three panels are expected to testify, including: individuals who claim to have suffered as a result of FDA regulation; physicians who say they need certain pharmaceuticals but are unable to obtain them; and outside interest groups. The agency will not be asked to testify. A similar hearing focusing on FDA regulation of medical devices was held March 30 ("The Gray Sheet" April 3, p. 8). The subcommittee is said to be planning two additional hearings for this summer, with one focusing on think-tank proposals for FDA reform and the other on FDA's views...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.